大剂量重组人红细胞生成素冲击治疗癌性贫血

Large Doses of Recombinant Human Erythropoietin Pulse Therapy for Cancer-Related Anemia

目的观察大剂量重组人红细胞生成素(RHEpo)冲击治疗癌性贫血的疗效及副反应。方法 98例患者随机分入试验组或对照组。试验组采用大剂量RHEpo冲击法,对照组接受RHEpo常规剂量法。观察有效率、HbV、输血率及RHEpo不良反应。结果试验组治疗2周后HbV明显升高(P<0.01),对照组4周后HbV明显升高(P<0.01);试验组4、6周HbV高于对照组(P<0.05);试验组2、4、6周有效率为39.6%、58.3%、79.2%,高于对照组的17.0%、29.9%、51.1%(P<0.05,P<0.01);两组间输血率及药物不良反应率无明显差异。结论大剂量RHEpo冲击治疗癌性贫血的疗效优于常规剂量法,不良反应无增加。

Objective To observe the therapeutic efficacy and adverse reactions of large doses of recombinant human erythro- poietin（RHEpo） pulse therapy for cancer-related anemia. Methods All 98 patients were randomly divided into experimental group and control group. The patients in the experimental group were treated with large doses of recombinant human erythropoietin pulse therapy, while the patients in the control were treated with conventional doses of recombinant human erythropoietin. The ef-fective rate, hemoglobin value, blood transfusion rate and adverse reactions were recorded. Results After 2 weeks of treatment, hemoglobin values of the experimental group were significantly increased （P 〈 0.01 ） ;After 4 weeks of treatment, the level of he-moglobin in control group increased significantly（P 〈0.01 ）. Hemoglobin values of 4,6 weeks of experimental group were higher than those of the control group（ P 〈 0.05 ）. The effective rate of 2,4,6 weeks of the experimental group were 39.6% ,58.3% and 79.2% ,respectively;and was higher than 17.0% ,29.9% and 51.1% in the control group（P 〈0.05 or P 〈0.01 ）. There was no difference in blood transfusion rates and adverse reaction rates between the two groups. Conclusion The impact of large doses of recombinant human erythropoietin pulse therapy is superior to the conventional-dose method for the cancer-related anemia, without significant increase in side reactions.